Investor Relations

Amicus Therapeutics (NASDAQ: FOLD) is pioneering a paradigm-shifting approach to treating a range of human genetic diseases in which crucial proteins are misfolded, thus reducing or eliminating their functionality. Amicus develops pharmacological chaperones - oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity. This novel, next-generation approach offers the potential to improve treatment options for patients with genetic diseases.

2010 Proxy Materials

Recent Releases

Jan 23, 2012
Amicus Therapeutics Appoints Bradley L. Campbell as Chief Business Officer

Jan 9, 2012
Amicus Therapeutics Provides Full-Year 2012 Strategic Outlook and Financial Guidance

Events

Jan 12, 2012
Amicus Therapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference

Nov 16, 2011
Lazard Capital Markets 8th Annual Healthcare Conference